UPDATE: Short-Seller Article on Ligand (LGND) is Silly, Underlying Strength Remains - Roth Capital
Tweet Send to a Friend
(Updated - June 17, 2014 8:54 AM EDT)
Roth Capital keeps Ligand Pharma (Nasdaq; LGND) at Buy with a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Roth Capital keeps Ligand Pharma (Nasdaq; LGND) at Buy with a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE